January 17th 2025
Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.
Type 2 Diabetes, Metformin, and Cardioprotection: Are the Data There?
May 14th 2013Metformin and the class of sulfonylureas are the "work horses" of therapy for type 2 diabetes. Metformin even confers some protection from vascular complications. But, how do they stack up against newer agents? Here, a closer look.
Novel Risk Factors Improve Prediction of Cardiovascular Disease in Intermediate-Risk Persons
February 12th 2013It has been predicted that costs for cardiovascular disease will increase to more than $1 trillion dollars annually in the US by 2030. If statins are effective in preventing heart disease, why are costs still rising?